搜索
1

1

News Center
/
/
Company news
11-11

Make an Appointment with AIVD at MEDICA 2022

We are happy to announce that AIVD is going to exhibit at MEDICA 2022 from November 14th to 17th in Düsseldorf.
10-31

Innovation, Win-Win - AIVD CACLP 2022 Highlights Review

On October 26-28, 2022, the 19th China Association of Clinical Laboratory Practice Expo (CACLP) was successfully held in Nanchang, China, where more than 1400 in vitro diagnostic companies from the whole industry chain gathered to share this industry feast.
10-19

AIVD successfully developed a 25-OH-D assay with a clinical compound rate of >95%

25-OH-D plays an important physiological role in osteoporosis, rickets, chronic kidney disease (CKD) and skin diseases, especially in the regulation of calcium and phosphorus metabolism and maintenance of bone health, while its role in muscle, cardiovascular disease, diabetes, cancer, autoimmune and inflammatory responses is also gaining attention.
09-08

The performance of the AIVD glycosylated hemoglobin paired antibody and chromatography uncut sheet is comparable to that of well-known international brands

According to the International Diabetes Federation, glycated hemoglobin (HbA1c) is the "gold standard" for monitoring diabetes and is crucial for both diagnosing and treating the condition. The glycated hemoglobin level has significant therapeutic relevance for assessing the overall control of blood sugar, identifying treatment-related issues, and directing treatment strategies in the management of diabetes.
09-07

Monkeypox Virus(MPV) Antigen Rapid Test Uncut Sheet

Based on its advantages in raw material research and development, AIVD has created a monkeypox virus antigen test kit uncut sheet. The product has a high sensitivity, high specificity, clear and easy to interpret results, etc. after numerous verifications. It is appropriate for the detection of samples such as saliva, throat swabs, whole blood, serum, and plasma.
08-22

HIV/HCV/TP POCT Testing Solutions

HIV/HCV/TP are three infectious diseases that are globally prevalent and have a high risk. After the human body is infected with HIV, HCV and TP, antibodies to the corresponding pathogens appear in the blood.
08-10

HIV Ⅰ/Ⅱ Rapid Testing Solutions

Human immunodeficiency virus (HIV) is the causative agent of AIDS, and is highly contagious and susceptible to all kinds of people. After the HIV invades the human body, it destroys the body’s immune system, causing the infected person to lose immunity gradually, and eventually leads to death. HIV is divided into two subtypes, HIV 1 and HIV 2. After the human body is infected with the virus, the corresponding antibodies generally appear within 1 to 3 months.
07-26

Looking for POCT Distributors

As a manufacturer of complete solutions for IVD industry, AIVD Biotech has 37 POCT kits with CE approval. The list of certified products covers COVID-19 antigen kit, FLU A/B combo rapid test and various fluorescnece immunoassay (FIA) solutions for cardiac markers, inflammation, hormones, thyroid function, kidney function, blood sugar, anemia, digestive tract, infectious diseases, etc..
07-19

Monkeypox Rapid Testing Solutions

Monkeypox is a virus that is generally spread through close or intimate contact, with symptoms that include a rash and fever. It is much less transmissible than fast-spreading respiratory diseases like COVID-19, however, the virus is spreading globally and requires a comprehensive international government and community response to provide vaccines, testing, and treatments.
04-14

The first in China | AIVD launched six diagnostic raw materials for self-developed new thrombosis

The pathological process of thrombotic diseases involves three major systems: vascular endothelium, coagulation and fibrinolysis. It has been confirmed that in the prethrombotic state, the vascular endothelium, coagulation and fibrinolysis systems have been changed. TAT, PIC, TM, t-PAIC, FDP and D-Dimer are effective responses to the early changes of the body's vascular endothelium, coagulation and fibrinolysis systems. effective indicator. It is suitable for early diagnosis and risk assessment of high-risk groups of thrombosis in various clinical departments.
Previous page
1
2

Shenzhen AIVD Biotechnology Co. , LTD.

A4 Building 4th Floor / B5 Building C501, China Merchants Bright Technology Park, Fenghuang Street, Guangming District, Shenzhen, Guangdong Province, China

E-mail:market@aivdbiotech.com 
             info@aivdbiotech.com

Tel:+86-755-26165742   +86 18543132823

WhatsApp:+86 18543132823

facebook facebook facebook facebook facebook

© 2022 Shenzhen AIVD Biotechnology Co.,LTD.     粤ICP备18093805号